Ocular toxoplasmosis

Summary

Ocular toxoplasmosis (MONDO:0005879) is a disease and 3 clinical trials. A subtype of toxoplasmosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ocular toxoplasmosis
Mondo ID	MONDO:0005879
EFO	EFO:0007399
MeSH	D014126
SNOMED CT	416481006
UMLS	C0040561
MedGen	21599
Anatomy (UBERON)	UBERON:0010230
Is cancer (heuristic)	no

Disease family

This is a subtype of toxoplasmosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › coccidiosis › toxoplasmosis › ocular toxoplasmosis

Related subtypes (2): cerebral toxoplasmosis, congenital toxoplasmosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Sulfamethoxazole	Phase 3 (in late-stage trials)
Trimethoprim	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01449877	PHASE3	COMPLETED	Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis
NCT03948750	Not specified	COMPLETED	Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis
NCT04219176	Not specified	COMPLETED	Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis